The pharmaceutical industry is highly volatile, with promising lead candidates making or breaking a company’s year.
Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies and research organizations to enable them to develop the next leading drug in the market, observes GlobalData, a leading data and analytics company.
The $8.5 billion agreement between AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) to co-develop AstraZeneca’s Lynparza (olaparib) for multiple cancer types puts the two companies at the top for strategic alliance spending for 2017. AstraZeneca just clinched the top spot from Merck with its development deals with Pieris Pharmaceuticals (Nasdaq: PIRS) and MedImmune.
Lisa Marris, healthcare analyst at GlobalData, comments: “Despite this, Merck has had an arguably more successful year. It more than quadrupled its alliance deal values since 2016, and if its subsidiaries are added to the equation, its 2017 deal values rise to $9.5 billion, an increase of 248% from 2016, whereas AstraZeneca and its subsidiaries stayed almost stagnant at $11 billion.
Also big year for Pieris
Pieris Pharmaceuticals also saw a good year, making alliances in 2017 worth more than 35 times those it made in 2016. However, it is unlikely to do as well this year, as the 2017 value was primarily due to its $2.2 billion co-development deal with AstraZeneca, alongside a $1.8 billion licensing agreement with Frances’ Servier.
Ms Marris continues: “The development agreement with AstraZeneca will help Pieris enhance its inhaled drug candidates for respiratory diseases, whereas the collaboration with Servier will advance Pieris’ immune-oncology programs, led primarily by PRS-332, a PD-1-targeting bispecific checkpoint inhibitor.”
[NB: Not included in the GlobalData analysis, just last week, Pieris signed up another deal, with a potential of $1.2 billion in upfront and milestone payments with Seattle Genetics.]
Allergan and Novartis both experienced slower years than 2016, with decreases in partnership and licensing deal value by 44% and 5%, respectively. However, both companies still closed big deals in 2017. Allergan entered into a $2.8 billion licensing agreement with Assembly Bioscience to acquire microbiome gastrointestinal (GI) development programs. Novartis entered into almost double the number of deals it had in 2016, and closed two $1 billion deals in cardiovascular and eye indications with Ionis Pharma and Tribos, respectively.
GlobalData expects that 2018 is likely to be Merck’s year in terms of research and development collaboration.
Source: The Pharma Letter
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
